You Can’t Patent LSD
Investor interest waned in psychedelic stocks since 2021. Valuations collapsed, but research continued. Phase III trials for psilocybin treatments are now happening.
Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Mary Long caught up with Motley Fool Contributor Keith Speights to check in on the psychedelic industry. They discuss:
- Advice to investors looking at a highly speculative industry.
- The cash and regulatory questions for these companies.
- Key differences between the cannabis market and psychedelic stocks.
- The challenges of doing a double-blind test on psychedelic compounds.
Companies discussed: CMPS, CYBN, ATAI
Host: Mary Long
Guest: Keith Speights
Producer: Ricky Mulvey
Engineers: Rick Engdahl, Desireé Jones
Learn more about your ad choices. Visit megaphone.fm/adchoices